Potential Thrombogenic Complications With the Use of Recombinant Activated Factor VII in Combat Trauma

Hoots WK Challenges in the therapeutic use of a “so-called” universal hemostatic agent: recombinant factor VIIa. Hematology Am Soc Hematol Educ Program. 2005;426-431.

Stein DM , Dutton RP , O'Connor J. , Alexander M. , Scalea TM Determinants of futility of administration of recombinant factor VIIa in trauma . Trauma. 2005;59:609-615.

MacLaren R. Weber LA , Brake H. , Gardner MA , Tanzi M. A multicenter assessment of recombinant factor viia off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45:1434-1438.

Midla GS Recombinant factor VIIa and its clinical applications. Army Med Department Journal. PB 8-04-7/8/9 Jul/ Aug/Sep.